Omnicell (NASDAQ:OMCL) Releases FY 2024 Earnings Guidance

Omnicell (NASDAQ:OMCL) updated its FY 2024 earnings guidance on Wednesday. The company provided EPS guidance of 1.650-1.720 for the period, compared to the consensus EPS estimate of 1.370. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion. Omnicell also updated its Q4 guidance to $0.55-$0.62 EPS.

Omnicell Trading Up 0.1 %

Shares of NASDAQ OMCL traded up $0.03 during midday trading on Friday, hitting $48.67. 683,792 shares of the stock traded hands, compared to its average volume of 528,146. Omnicell has a one year low of $25.12 and a one year high of $55.74. The business has a 50 day moving average price of $43.26 and a two-hundred day moving average price of $35.17. The company has a current ratio of 1.05, a quick ratio of 2.22 and a debt-to-equity ratio of 0.47.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, August 1st. The company reported $0.51 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.37. The firm had revenue of $276.80 million for the quarter, compared to the consensus estimate of $254.41 million. Omnicell had a negative net margin of 1.66% and a positive return on equity of 2.55%. The business’s revenue was down 7.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.29 earnings per share. On average, equities analysts forecast that Omnicell will post 0.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

OMCL has been the topic of several recent research reports. Bank of America reaffirmed a “neutral” rating and issued a $57.00 price target (up previously from $44.00) on shares of Omnicell in a research report on Thursday. JPMorgan Chase & Co. lifted their target price on Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a research report on Friday, August 23rd. Barclays increased their price target on Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research report on Thursday. Benchmark reaffirmed a “buy” rating and set a $48.00 price objective on shares of Omnicell in a report on Wednesday, October 9th. Finally, Craig Hallum increased their target price on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a report on Thursday. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $49.14.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.